A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...
SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJAMA Otolaryngology–Head & Neck Surgery·DateAug 13, 2026
A new study examines the KEYNOTE-689 trial cohort to determine whether anticipated survival benefits outweigh the costs based on a standard threshold. Patients with higher combined positive scores saw significant quality-adjusted life years gains with perioperative pembrolizumab.
SourceMichigan Medicine - University of Michigan·JournalJAMA Otolaryngology–Head & Neck Surgery·TypeData/statistical analysis·DateAug 10, 2026
Researchers found that IVMT-Rx-4 selectively blocks the function of the MDA-9/Syntenin protein, limiting tumor growth and eliminating therapy resistance in preclinical cancer models. The study suggests a new targeted treatment option for head and neck squamous cell carcinoma.
SourceVirginia Commonwealth University·JournalCancer Letters·DateAug 5, 2026
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Liquid biopsy targeting viral ctDNA holds promise as a diagnostic and surveillance tool for head and neck cancer. The study aims to monitor treatment response and assess minimal residual disease (MRD) to adapt treatment via precision oncology.
SourceJAMA Network·JournalJAMA Otolaryngology–Head & Neck Surgery·DateJul 30, 2026
A multidisciplinary consensus updates treatment guidance for prolactinomas, emphasizing early recognition, individualized management strategies, and advanced imaging. The recommendations cover screening, assessment, diagnosis, treatment, and long-term monitoring to improve patient outcomes and quality of life.
SourceChinese Neurosurgical Journal·JournalChinese Neurosurgical Journal·TypeSystematic review·DateJul 13, 2026
A Phase I/II clinical trial of the HPV therapeutic vaccine PepCan found it to be well-tolerated, with mild injection-site reactions being the most common adverse events. However, the study did not demonstrate a reduction in head and neck cancer recurrence rates, likely due to its small sample size.
SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateJun 15, 2026
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
AmScope B120C-5M Compound Microscope
AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.
A new study found that HPV-DeepSeek, an ultrasensitive blood test, can identify patients with HPV-associated head and neck cancer who may benefit from additional treatments. The test detected circulating tumor DNA in 98.1% of patients at diagnosis, significantly improving detection rates compared to existing methods.
SourceMass General Brigham·TypeObservational study·DateJun 10, 2026
A population-based screening trial evaluating a cell-free DNA multicancer early detection test found modest increases in diagnostic delay rates for head and neck, lung, and upper gastrointestinal cancers. These findings suggest that future trials may need to consider system-level spillover effects on healthcare resources.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
A new study aims to make proton therapy available to more patients in Europe by planning five new centres across Romania, Greece, Italy, Northern Ireland, and Poland. Currently, 59% of European cancer patients have access to the treatment, but this can be increased to 87% with strategic location and expansion.
SourceEuropean Society for Radiotherapy and Oncology (ESTRO)·TypeComputational simulation/modeling·DateMay 14, 2026
A study by Medical University of Vienna shows that PET/CT scans can detect aggressive forms of head and neck cancer at an early stage due to specific patterns reflecting biological activity. Modern imaging helps identify targeted treatment strategies for a type of cancer difficult to treat.
SourceMedical University of Vienna·JournalMolecular Cancer·DateMay 13, 2026
Four new OICR-funded studies using CATALYST will advance cancer insights by reanalyzing existing patient samples and data. The initiatives aim to improve cancer detection, diagnosis, and treatment by building on previous research.
SourceOntario Institute for Cancer Research·DateMay 13, 2026
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
SourceUniversity of Miami Miller School of Medicine·DateMay 6, 2026
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers have shown that extracts from bioengineered chewing gum reduce levels of three microbes linked to worse outcomes in oral cancers, including HPV and bacteria Pg and Fn. The findings support the value of advancing these therapies to clinical trials as adjuvants or prophylaxis.
SourceUniversity of Pennsylvania·JournalScientific Reports·TypeExperimental study·DateApr 22, 2026
A new treatment using low-dose nivolumab injections into precancerous oral lesions significantly reduced lesion size and risk of cancer progression. The study showed a 60% average reduction in lesion size and complete pathologic response in six patients, with no dose-limiting side effects.
SourceUniversity of Texas M. D. Anderson Cancer Center·DateApr 21, 2026
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...
SourceAlliance for Clinical Trials in Oncology·DateApr 20, 2026
A new study led by Dartmouth Cancer Center identifies key barriers to timely head and neck cancer treatment in rural areas, including transportation and caregiver challenges. The research highlights the importance of dedicated staff, strong community ties, and peer support in navigating the complexity of cancer care.
SourceDartmouth Health·JournalJAMA Otolaryngology–Head & Neck Surgery·TypeSurvey·DateApr 16, 2026
A new study reveals that oral cavity cancer in younger adults is increasingly presenting as tongue cancer, affecting women disproportionately. Despite the trend of later-stage diagnosis, survival rates have shown modest improvement across all tumor sites and stages.
SourceAmerican Academy of Otolaryngology - Head and Neck Surgery·DateApr 6, 2026
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
Researchers developed a blood-based test that analyzes circulating tumor HPV DNA to inform personalized treatment strategies for HPV-associated throat cancer. The study found that ctDNA levels change before and after surgery, influenced by tumor biology and kidney function.
SourceOhio State University Wexner Medical Center·JournalJAMA Otolaryngology–Head & Neck Surgery·DateApr 2, 2026
The study discovered that restoring cellular vibration decreases cancer growth and severity in laryngeal cancer. Researchers exposed cancer cells to sound-wave vibration, leading to a decrease in a protein promoting cancer growth.
SourceUniversity of Turku·JournalNature Materials·DateMar 4, 2026
A new review study led by the University of Maryland School of Medicine identifies genetic ancestry as a key component of assessing head and neck cancerous tumors. The research found that ancestry, rather than self-identified race, was a stronger predictor of genetic differences between tumors.
SourceUniversity of Maryland School of Medicine·JournalCancer and Metastasis Reviews·TypeSystematic review·DateJan 30, 2026
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
SourceUniversity of Leicester·JournalThe Lancet·TypeComputational simulation/modeling·DateJan 30, 2026
Researchers developed a novel combined PET imaging approach to personalize radiotherapy for head and neck cancers, creating biologic maps that show tumor characteristics. This strategy led to greater than 90% predicted tumor control probability, outperforming previous literature.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 28, 2026
Research suggests that blocking growth factor receptor signaling using cancer drugs may overcome two challenges: managing oral cancer pain and preventing opioid tolerance. This approach could control cancer while addressing pain through a non-opioid, biologically rational approach.
SourceNew York University·JournalScience Signaling·DateJan 27, 2026
A new Phase II trial will examine whether giving chemotherapy or chemotherapy combined with immunotherapy before surgery can improve survival compared to surgery alone. The trial aims to identify a treatment that will help patients live longer without the cancer returning.
SourceUniversity of Oklahoma·TypeRandomized controlled/clinical trial·DateJan 27, 2026
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
SourceUniversity of Texas M. D. Anderson Cancer Center·DateJan 9, 2026
Sky & Telescope Pocket Sky Atlas, 2nd Edition
Sky & Telescope Pocket Sky Atlas, 2nd Edition is a durable star atlas for planning sessions, identifying targets, and teaching celestial navigation.
Researchers developed an artificial saliva containing sugarcane protein, CANECPI-5, to aid in treating teeth of patients with head and neck cancer. The solution significantly reduced bacterial activity and tooth demineralization when combined with fluoride and xylitol.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Dentistry·DateJan 7, 2026
Researchers discovered that high levels of protein BATF2 drive tumor immune suppression in head and neck cancer. Glutamine in the tumor microenvironment silences BATF2, affecting the STING signaling pathway and overall immune response.
SourceUniversity of Texas M. D. Anderson Cancer Center·DateJan 7, 2026
Two studies found that elevated bacteria levels in tumors weaken immune response, driving resistance to immunotherapy. Researchers are now exploring how to identify patients most likely to benefit from immunotherapy and develop targeted interventions to restore its effectiveness.
SourceCleveland Clinic·JournalNature Cancer·DateJan 2, 2026
Researchers developed an AI-based noninvasive tool to predict oropharyngeal cancer spread, identifying patients who should receive aggressive treatment or undergo de-intensification. The tool improved risk stratification, enabling more accurate predictions of survival and cancer spread.
SourceMass General Brigham·JournalJournal of Clinical Oncology·TypeImaging analysis·DateDec 23, 2025
A recent study analyzing over 1,400 cases of squamous cell carcinoma found that more aggressive histopathological variants occur at a rate of 4.6%, significantly lower than previous estimates. The researchers highlight the importance of considering regional differences in tumor origin and behavior to improve treatment outcomes.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalAnnals of Diagnostic Pathology·DateDec 18, 2025
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
Researchers found that patients with low physical activity levels are at higher risk of developing lymphedema. The study used a lymph scanner to measure tissue water and identified limits for what is considered lymphedema. Regular physical activity may help reduce the risk of lymphedema after head and neck cancer treatment.
SourceLund University·JournalOral Oncology·TypeObservational study·DateDec 17, 2025
Researchers at UT Health San Antonio School of Dentistry are studying novel targets and approaches to treat oral squamous cell carcinoma, the most common type of oral cancer. The studies aim to reduce pain management and mucositis in patients undergoing radiotherapy.
SourceThe University of Texas at San Antonio Health Science Center·DateNov 7, 2025
A new study from Memorial Sloan Kettering Cancer Center identifies unique genetic signatures in cancer patients of non-European ancestry and finds adding immunotherapy can boost effectiveness for hard-to-treat follicular lymphomas. Additionally, researchers discover a web-based system to report head-and-neck cancer concerns, leading to...
SourceMemorial Sloan Kettering Cancer Center·DateOct 31, 2025
A new blood-based liquid biopsy model, LiBIO score, predicts immunotherapy response with high accuracy. The model identifies an early post-treatment time point as optimal for assessing treatment response and can help identify patients who are more likely to benefit from immunotherapy.
SourceUniversity of Illinois Urbana-Champaign Cancer Center at Illinois·JournalNature Communications·DateOct 22, 2025
Garmin GPSMAP 67i with inReach
Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.
Surgeons at Vanderbilt University Medical Center have successfully performed the country's first procedure using a device that combines PET and CT scans to aid in accurate staging and therapy response assessment. The use of this technology may allow surgeons to immediately assess the success of resection in achieving a negative margin.
A phase III trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. Excellent tumor control and fewer long-term side effects were seen with both treatments.
SourceAmerican Society for Radiation Oncology·DateSep 29, 2025
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
SourceUniversity of California - Los Angeles Health Sciences·DateSep 26, 2025
A new liquid biopsy tool, HPV-DeepSeek, can identify HPV-associated head and neck cancer in asymptomatic individuals up to 10 years before diagnosis. The test uses whole-genome sequencing to detect microscopic fragments of HPV DNA in the blood.
SourceMass General Brigham·JournalJNCI Journal of the National Cancer Institute·TypeData/statistical analysis·DateSep 9, 2025
Researchers have developed a new technique to measure boron in individual cancer cells, enabling the study of how drugs interact with tumour cells. This breakthrough could lead to more effective treatments for head and neck cancers.
SourceUniversity of Birmingham·JournalJournal of Analytical Atomic Spectrometry·TypeExperimental study·DateSep 9, 2025
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
SourceUniversity of Texas M. D. Anderson Cancer Center·DateSep 5, 2025
The ASTRO's 2025 Annual Meeting will feature pivotal studies in radiation medicine, highlighting advances in radiopharmaceutical therapy and new indications for low-dose radiation therapy. The meeting will also explore cutting-edge techniques for prostate, breast, lung, and other common cancers.
SourceAmerican Society for Radiation Oncology·DateSep 4, 2025
A new mitochondrial-targeting drug, LCL768, has been developed to attack head and neck cancer cells by damaging their mitochondria. The drug's ability to increase ceramide levels inside mitochondria triggers mitophagy, leading to cancer cell death.
SourceMedical University of South Carolina·JournalCancer Research·TypeExperimental study·DateSep 2, 2025
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
A new class of targeted therapy showed promise in treating head and neck squamous cell carcinoma (HNSCC) in pet cats, with 35% of patients experiencing controlled disease. The drug, which targets the transcription factor STAT3, also raised levels of PD-1, a protein associated with an immune response to cancer.
SourceCell Press·JournalCancer Cell·TypeRandomized controlled/clinical trial·DateAug 28, 2025
A phase 2 clinical trial found that autologous tumor-infiltrating lymphocyte (TIL) cell therapy helped stabilize metastatic head and neck squamous cell carcinoma (HNSCC) in some patients. The median response duration was 7.6 months, with cancer stabilization occurring in 64% of patients.
SourceUniversity of North Carolina Health Care·JournalJournal for ImmunoTherapy of Cancer·TypeRandomized controlled/clinical trial·DateAug 28, 2025
Researchers found that HPV16 undermines the body's defenses by reprogramming immune cells surrounding tumors. Blocking IL-23 boosts experimental treatments for HPV to eliminate cancer cells.
SourceKeck School of Medicine of USC·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateAug 19, 2025
Apple AirPods Pro (2nd Generation, USB-C)
Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.
The researchers developed a novel approach to virtual contrast enhancement in MRI imaging, using pixelwise gradient methods with Generative Adversarial Networks. The model excelled in capturing intricate details and textures, outperforming its predecessor in texture representation.
SourceThe Hong Kong Polytechnic University·JournalInternational Journal of Radiation Oncology*Biology*Physics·DateAug 13, 2025
Researchers at the University of Oklahoma are conducting a first-of-its-kind study to investigate the effect of cannabis use on facial wound healing in head and neck cancer patients. The study aims to determine whether cannabis smoking negatively affects wound healing, with potential implications for other types of surgery and conditions.
Researchers have developed an AI system that can recognize the early warning stages of laryngeal cancer from voice recordings. By analyzing variations in tone, pitch, and volume, the AI can distinguish between voices with benign vocal fold lesions and those with cancer. The study's findings offer a promising breakthrough for non-invasi...
SourceFrontiers·JournalFrontiers in Digital Health·TypeExperimental study·DateAug 12, 2025
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Researchers at UC San Diego School of Medicine have developed a novel approach to enhance the effectiveness of immunotherapy treatments for head and neck squamous cell carcinomas (HNSCC). Delivering radiation therapy that preserves tumor-draining lymph nodes followed by immunotherapy resulted in a complete and durable tumor response in...
SourceUniversity of California - San Diego·JournalNature Communications·DateJul 28, 2025
Researchers have identified a novel diagnostic tool that can predict patient outcomes for head and neck squamous cell carcinoma. The LIMA1-alpha protein reliably identifies patients who can be cured with surgery alone, avoiding unnecessary oncological treatments.
SourceUniversity of Turku·JournalEMBO Molecular Medicine·DateJul 23, 2025
Researchers identified RTK dependent and independent mechanisms of resistance to EGFR targeted therapies in breast and head and neck cancers, highlighting opportunities for combination therapies and biomarker identification.
SourceImpact Journals LLC·JournalOncotarget·TypeSystematic review·DateJul 9, 2025
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
Brazilian researchers have identified a link between the oral bacteria Fusobacterium nucleatum and head and neck cancer, finding that its presence is associated with a more favorable prognosis. The study suggests that F. nucleatum may regulate immune factors, boosting the immune system's response and making tumors less aggressive.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Oral Microbiology·DateJun 26, 2025
A new liquid biopsy blood test called HPV-DeepSeek achieved 99% sensitivity and specificity for diagnosing cancer in asymptomatic patients. The test detected fragments of the viral genome and other features in the blood, outperforming current methods in detecting HPV-associated head and neck cancers.
SourceMass General Brigham·JournalClinical Cancer Research·TypeExperimental study·DateMay 20, 2025
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
SourceUniversity of Southampton·JournalNature Communications·TypeExperimental study·DateMay 1, 2025
A study found that most head-and-neck cancer survivors who underwent radiation don't know about survivorship care, despite grapple with side effects such as dry mouth, swallowing problems, and psychological distress. The survey also found that 40% of survivors still struggle with dry mouth and nearly a quarter reported trouble swallowing.
SourceNorthwestern University·JournalSupportive Care in Cancer·DateApr 29, 2025
A phase 3 clinical trial showed that pembrolizumab before and after standard-of-care surgery significantly extends event-free survival and substantially shrinks tumors in head and neck cancer patients. This regimen has improved outcomes without delays in surgery, marking a potential new standard of care for this patient population.
GQ GMC-500Plus Geiger Counter
GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.
A phase III clinical trial found that adding pembrolizumab before and after surgery improved responses and survival in patients with previously untreated, locally advanced head and neck squamous cell carcinoma. Patients treated with pembrolizumab were at least 27% less likely to have experienced recurrence.
SourceAmerican Association for Cancer Research·DateApr 27, 2025
A phase 3 clinical trial shows that adding pembrolizumab to standard-of-care therapy increases tumor shrinkage and prolongs cancer-free survival by nearly two years. Patients with locally advanced head and neck cancers benefited from this addition, marking a significant change in standard-of-care for the disease.